Experimental studies have shown that otilonium bromide (OB) inhibits both baseline and chemically or physically stimulated gastrointestinal motility. The spasmolytic activity of OB in the gastrointestinal tract occurs at doses that do not affect gastric secretion or produce typical atropine-like side-effects. The mechanism of action is composite: interference with calcium ion movement from intra-and extracellular sites; blockade of calcium channels; and binding to muscarinic receptors and tachykinin neurokinin-2 receptors. Pharmacokinetic studies have shown that OB accumulates in the lower intestine and has poor systemic absorption. Clinical studies have confirmed OB as a potent spasmolytic drug with a good tolerability profile. Studies in patients with irritable bowel syndrome demonstrated OB to be superior to placebo and reference drugs in parameters such as pain, abdominal distension and motility. The composite and local mechanism of OB action reduces hypermotility and modulates visceral sensation: factors thought to be responsible for pain improvement recorded in clinical trials. The compound is marketed worldwide and no serious adverse events have been reported as yet, confirming its excellent tolerability.
INTRODUCTION
Otilonium bromide (OB; Spasmomen, Doralin, Spasmoctyl [Menarini Group, Italy]), which is a quaternary ammonium salt that has gastrointestinal spasmolytic properties. is used worldwide for the treatment of irritable bowel syndrome (IBS).
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Otilonium bromide and the gastrointestinal tract
The most common disease diagnosed by gastroenterologists is IBS, and it affects about 20% of the population.' Three major mechanisms are involved in IBS: psychosocial factors; altered motility; and disturbed sensory function of the gut. The myorelaxant effect exerted by DB in reducing gut spasm is thought to improve pain and sensory function in IBS. 2 , :l In comparison with baseline or placebo, parameters such as pain, abdominal distension, degree of motility and incomplete emptying have been shown to differ significantly in patients treated with DB. A meta-analysis by Poynard et aJ.2 established DB as a first-line treatment for IBS, taking into account the global assessment, pain improvement and absence of side-effects found with DB treatment.
In the past few years, further knowledge concerning the composite mechanism of action of DB has been gained," -7 and one large-scale clinical trial has confirmed its beneficial effects in patients with IBS.3 In particular, the actions of DB on muscarinic receptors, tachykinin neurokinin-2 (NKzl receptors and on calcium channels have been characterized, and these properties may account for its ability to reduce both stimulated intestinal motility and altered sensitivity in patients with IBS. In view of this, it seems appropriate to provide an update on the preclinical pharmacology, pharmacokinetics and clinical efficacy of DB.
PRECLINICAL STUDIES
The compound DB (diethylmethyl lz-l-t-lzocty loxybenzamido )benzoy loxy] -ethy l} ammonium bromide; Fig. 1 ), discovered and developed by Menarini Research SpA, has potent smooth muscle relaxant activity." The positively charged nitrogen atom is responsible for the poor systemic absorption and low penetration of the drug into the central nervous system, whereas the long aliphatic chain favours binding to cell membranes in target tissues, resulting in a long duration of pharmacological effects.
IN VIVO STUDIES
Various agents, including betanechol, carbachol, cholecystokinin (CCK)-7, CCK-8, ceruleine, eledoisin, eserine, glycerol, methochlorpramide and physalaemin, as well as electrical stimulation, increased the motility of the gastrointestinal tract in dog, guinea-pig and rat. The administration of DB
FIGURE 1
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Structural formula of otilonium bromide.
antagonized this stimulated motility. 9 -13 After intravenous (5 -10 mg/kg) or oral (10 -100 mg/kg) administration, OB reduced spontaneous or postprandial motility (Fig. 2) , and partially or totally inhibited the stimulation of gastrointestinal motility induced by carbachol, CCK-8, or glycerol.
The different segments of the gastrointestinal tract showed widely varying sensitivity to the spasmolytic activity of OB, as shown in the rat after local application of carbachol to the serosal surface of the different segments tested."! In these experiments, OB spasmolytic effectiveness decreased in the order stomach > colon > duodenum-ileum > caecum-jejunum > rectum. Peristaltic activity was uninfluenced by OB. Conversely, in the same model, N-butylscopolamine bromide, a competitive anticholinergic agent, was more effective in the upper than in the lower gastrointestinal tract. This is in accordance with the greater cholinergic innervation of the proximal compared with the distal portion of gastrointestinal tract.!"
IN VITRO STUDIES
The smooth muscle relaxant activity of OB has been investigated in the gastrointestinal, vascular and respiratory systems. Spontaneous and stimulated motility of the gastrointestinal tract, induced by acetylcholine, barium chloride, carbachol, furtretonium, histamine, nicotine, platelet activating factor (PAF), serotonin, substance P and electrical stimulation, has been shown to be inhibited by OB,4,5,7,9,13,15 -18 Addition of OB resulted in competitive antagonism of barium chloride-induced contractions of rat ileum and aorta, calcium chloride (in high potassium, calcium-free medium) and potassium-induced contraction of rat colon and aorta, and carbachol-induced contraction of rat colon (in high potassium, calcium-free medium). This suggests that an interference with calcium availability for the 
Effect of intravenous otilonium bromide (OB) on gastrointestinal postprandial motility in
dogs. 13 contraction process is responsible for the smooth muscle relaxant effects of DB. 16, 17, 19 Further evidence to support this is provided by Gandfa et 01.,4 who showed that DB blocked calcium entry into chromaffin cells by blocking voltage-dependent calcium channels.
TISSUE SELECTIVITY
Regardless of the nature of agonist, the spasmolytic activity of DB is preferentially exerted on gastrointestinal, compared with vascular or respiratory smooth muscle, Hi and in vitro studies have shown that the colon is more sensitive to the relaxing activity of DB than other gastrointestinal segments.l'' When administered orally at doses that produced spasmolytic effects, DB was devoid of central and peripheral atropine-like side-effects, in studies specifically designed to detect cholinergic antagonism, and did not inhibit gastrointestinal secretion.P-"
MECHANISM OF ACTION
The predominant action of DB is thought to be the modification of calcium fluxes from intraand extracellular sites. 4, 16, 17, 19 At concentrations of 10 -50 lIM, DB inhibits calcium influx and a decrease in smooth muscle tension has been demonstrated in isolated guinea-pig ileum depolarized by high concentrations of potassiurn.P A direct action of DB on contractile proteins has been demonstrated in skinned muscle fibre preparations (Le. muscle fibres lacking a membrane) derived from rabbit ear artery." A concentration-dependent decrease in contractility was induced by DB (1 -100 lIM), but no effect on sodium fast channels or phosphodiesterase activity was observed, ruling out a local anaesthetic and a papaverine-like action of DB.
A recent paper investigated the electrical and mechanical responses induced by different stimuli in the circular muscle of guinea-pig proximal colon." At concentrations in the lIM range, DB inhibited the contractility initiated by the three main receptors for excitatory transmitters present in the mammalian intestine (muscarinic and tachykinin NK 1 and NK 2 receptors). Moreover, DB acts as a tachykinin NK 2 receptor antagonist at these concentrations and may block NK 2 expression on certain visceral efferent nerves, thus modulating the development of intestinal hyperalgesia. 21 Further information on the mechanism of action of DB has come from molecular pharmacology studies. The binding profiles of 60 different receptors and ion channels have shown that DB possesses sub-ulvl affinity for muscarinic M 1 , M 2 , M 4 , M s and PAF receptors, and a lIM affinity for L-type calcium channels." On the other hand, DB is poorly absorbed, and specific binding sites for the drug in the gastrointestinal tract have been demonstrated, In vivo (oral and intracolonic administration analysed by autoradiography) and in vitro studies have shown that the highest specific binding of DB was found in the muscle layer of colon and recturn." Indeed, binding studies in the rat colon have shown that DB competitively interacts with verapamil binding sites on L-type calcium channels and with muscarinic M, receptors (with an inhibitory concentration 50 [IC so ] of 1.02 and 1.22 lIM, respectively),"
All these findings provide a molecular background to elucidate the spasmolytic activity exerted by DB on intestinal smooth muscle. A combination of muscarinic receptor, tachykinin NK z receptor and calcium channel blocker properties seems to explain best the action of DB.
ANIMAL PHARMACOKINETICS
In the gastrointestinal tract of rats and dogs, [14C]-DB was poorly absorbed (5%), and did not cross the blood-brain barrier (Cochet P, Bromet N, 1999; data on file at Menarini Ricerche SpA), The absorbed fraction was rapidly eliminated from the circulation, the faeces being the most important route of elimination.
SELECTIVE UPTAKE AT THE LOWER GASTROINTESTINAL TRACT LEVEL
The anatomical localization of OB binding sites has been analysed by light microscopy autoradiography in rats. 22 Incubation of frozen sections of gastrointestinal tract with [14C]-OB (10 nM) showed that the radiolabel was specifically localized within colonic and rectal smooth muscle. Radiolabelled OB was also found in the stomach and small intestine, but the affinity for these tissues was at least 50 times lower compared with that for the large intestine ( Table 1) .
In vivo intracolonic administration of [14C]-OB resulted in a significant accumulation in the colon, and binding to the wall of the colon was dose-proportional. Within 15 min of administration, [14C]-OB was mainly located within the muscular layer. During this time 14C levels in the mucosa gradually declined.
A recent study illustrated the tropism of OB for the gastrointestinal tract (Cochet P, Bromet N, 1999; data on file at Menarini Ricerche SpA). Following oral administration of [14C]-OB (50 mg/kg), absorption was poor, with levels in plasma 1000 times lower than those in the gastrointestinal tract. Although OB was taken up by the intestinal wall, negligible concentrations were found in other tissues and persistent radioactive signalling (up to 24 h after dosing) was recorded only at the intestinal level ( Fig. 3 ).
HUMAN PHARMACOKINETICS
The low degree of OB absorption has been confirmed by pharmacokinetic studies performed in healthy subjects-? and in patients with IBS. 24 Radioactivity in whole blood, plasma, urine and faeces was determined after oral [14C]-OB (10 mg) administration to five healthy male subjects (Jochemsem R,
TABLE 1
Apparent dissociation constant (K d ) values of labelled otilonium bromide (['4C]-OB) bound
to frozen sections of rat gastrointestinal tract Crawley FEH, 1985; data on file at Menarini Ricerche SpA). Radioactivity of plasma was detectable only up to 6 h after drug administration. Mean peak plasma concentration of 10.8 ng equivalents/ml was found 2 h after dosing. Plasma levels were well below those exerting spasmolytic activity found with in vitro preparations. 4 . 5 ,7 .9 .13 ,l S - 18 The drug was almost completely excreted in the faeces (97.1% in 7 days), with only 0.7% being excreted in urine.
In another study in which OB (40 mg) was orally administered to six healthy volunteers, no OB was measureable in plasma of any subject, using gaschromatographic/mass spectrometry (lower limit of quantification, 10 ng/mll."
After local application of OB (300 mg) by endoscopy, the absorption and plasma level of OB (measured by high-performance liquid chromatography) was assessed in 10 patients 212 with IBS. 24 The OB plasma peak (mean 22 ± 17 ng/ml) was reached 1 h after dosing, but by 4 h in most of the patients plasma concentrations were undetected, or only trace amounts were present.
Following oral administration of [14CJ-OB (40 mg, 12 hand 30 min before surgical intervention) or intraluminal infusion of OB (150 mg) during colonoscopy, preferential localization of [14C]-OB in smooth muscle of the colon was detected, thus further suggesting selective tissue uptake (Amenta F, D'Amico L, 1988; data on file at Menarini Ricerche SpA).
(;LINICALPHARMACOLOGY
As shown in Table 2 , the ability of orally administered or locally applied OB to reduce hypermotility induced by several stimuli has been tested in healthy subjects and patients with IBS. The effect of single oral doses of DB (range 40 -240 mg) on distal and proximal gastrointestinal transit was recently assessed in 16 healthy subjects." Whole gut transit time was determined by timing the expulsion of faecal pellets. Expulsion time significantly (P = 0.025) increased by 4.1 h with DB (120 mg) compared with placebo, but at higher doses the median changes were not significant due to more extensive group variance. Gastric emptying of a 10% glucose solution (400 ml), tested by epigastric impedance, was slightly, but not significantly, delayed when results of the two highest DB doses were combined and compared with placebo. Orocaecal transit time (evaluated by lactulose breath-hydrogen method), however, was unchanged. Potential anticholinergic effects, such as visual accommodation and saliva flow, were unaltered and DB was well tolerated.
Narducci et a1. 26 measured colonic myoelectric activity and gastric emptying in 10 healthy subjects and in 10 patients with IBS. After a baseline, fasted state 30-min recording, DB (40 mg four times daily for 5 -7 days) was administered, and measurements were repeated for 3 h after ingestion of a 1000-kcal meal (Fig. 4) . Electrical activity was recorded by means of two bipolar electrodes inserted into the colonic mucosa, and the frequency of slow waves, the presence of spike potentials and the intraluminal pressure were determined. In patients with IBS, a significantly (P < 0.05) higher frequency of slow waves was detected compared with healthy controls. The frequency of spike potentials significantly (P < 0.01) increased after meals, both in patients and healthy subjects, but the increased motility persisted during late postprandial time in patients with IBS only. Thus, in patients with IBS, DB treatment can significantly reduce the magnitude and duration of gastrocolonic response to food (Fig. 4) .
Manometric measurement in five healthy subjects showed that local intrarectal infusion of DB (8 mg/5 ml per min; total dose 40 mg) was effective in reducing hypermotility induced by subcutaneous injection of betanechol chloride (5 mg)." Similar changes, measured manometrically, in response to DB were noted when intestinal motility was stimulated by injection of neostigmine (0.01 mg/kg) in nine patients with IBS. 28 A dose-dependent effect of DB (10 mg, 20 mg or 40 mg once daily) on abdominal pain, and latency and duration of analgesia was found in six patients with IBS in a placebo-controlled, double-blind study (Fig. 5 ). Tolerability of DB was good at all doses (Busachi C, Sotgiu G, 1974; data on file at Menarini Ricerche SpA).
The possibility of antimuscarinic side-effects occurring has been investigated in patients with IBS. Following DB administration no ocular changes or alteration of gastric pH were detected. 29.30
CLINICAL EFFICACY
Eight double-blind versus placebo, five comparative studies and one open study for a total of 2402 patients (1856 treated with DB, 546 with placebo or reference compounds) have been carried out in IBS with DB, largely using the standard therapeutic dose of 3 x 40 mg/day. The meta-analysis by Poynard et a1.,2 which took into account only some aspects of these studies, has ranked DB among the best smooth muscle relaxant agents in IBS treatment. This analysis has established the ability of DB to relieve abdominal pain in patients with IBS. Other studies have confirmed that symptoms, particularly abdominal pain, are improved in patients with IBS when treated with DB (20 mg three or four times dailyl.l": 37 Patients with IBS evaluated in a multicentre, double-blind, placebo-controlled, randomized study subjectively or objectively The results confirmed that treatment with DB significantly reduced abdominal pain. The number of painful episodes recorded in the intention-to-treat (ITT) population was significantly (P = 0.01) reduced after 10 weeks' treatment compared with placebo. After 15 weeks. the reduction in the incidence of pain was even more significant (P", 0.006). Similar results were obtained in the per-protocol (PP) population at 10 (P", 0.014) and 15 weeks (P", 0.006). Treatment with DB not only reduced the number of painful episodes, but also regulated the severity of the pain. Compared with placebo, DB was significantly more effective at reducing the severity of pain (P '" 0.056 and P '" 0.067 after 10 and 15 weeks, respectively) in the PP population. The effectiveness of DB on the frequency and severity of abdominal pain was confirmed by the effect on sigmoid colon sensation. After 10 weeks' treatment, the severity of sigmoid colon sensation at abdominal palpation significantly (P", 0.04) decreased in the DB group (ITT population) and after 15 weeks there was still a significant (P '" 0.045) decrease. In the ITT population, the incidence of success was for DB (87 cases [56.1%] compared with 216 65 cases [40.9%] with placebo; P '" 0.01). Success of therapy in the ITT population was significantly (P '" 0.029) higher in the DB group than with placebo.
The overall impact of DB on efficacy and tolerability assessed using the VAS of well-being was significantly higher than that of placebo. After 15 weeks, the mean VAS decreased from 5.82 ± 2.09 to 3.01 ± 2.21 in the DB group, and from 5.37 ± 2.04 to 3.28 ± 2.14 with placebo. The gain in efficacy with DB is significant (ITT, p", 0.048; PP population, p", 0.04) (Table 3) . After 15 weeks, treatment with DB resulted in a better global efficacy scale compared with placebo: the assessment was evaluated as good or excellent in 64.8% of the DB group compared with 48.3% of patients receiving placebo.
Baldi et aJ.:J8 evaluated the efficacy of DB (40 mg three times daily) compared otilonium bromide (DB) and placebo in visual analogue scale of well-being  (per-protocol analysis) with placebo by assessment of clinical (abdominal pain, abdominal bloat, frequency of defaecation) and functional criteria (distal sigmoid manometry recording the distension pain threshold using an intraluminal balloon) in a 4-week, doubleblind, parallel-group study. Unlike placebo (n = 37), OB (n = 34) significantly (P < 0.02), reduced abdominal pain and increased distension pain threshold. Neither of the two treatments affected frequency of defaecation. Sigmoid motility caused by bloat was significantly (P < 0.05) reduced with OB treatment, whereas it did not change with placebo.
Frequency and severity of abdominal pain, and subjective alterations of bowel habits were evaluated in 30 patients with IBS in a 4-week, double-blind, placebo-controlled, randomized study. :J9 The frequency of defaecation was not altered by OB (40 mg three times daily) or by placebo. Pain scores were significantly reduced in the OB group at the end of the treatment (week 4) compared with baseline (4.5 ± 2.4 versus 11.3 ± 3.5, P < 0.05), whereas this did not occur with placebo (7.3 ± 1.5 versus 8.6 ± 1.7). Episodes of incomplete emptying 217 were significantly less frequent during the last week of tteatment compared with pretreatment (1.6 ± 0.3 versus 2.7 ± 0.5, P < 0.05) in the active group, whereas with placebo no changes in this parameter were observed. The change in motility index between baseline and after stimulation with prostigmine was assessed by manometry. No statistically significant difference in intestinal transit times or stimulated motility was observed in OB or placebo group.
In patients with IBS, the effectiveness of OB (40 mg three times daily) in association with a normal diet (n = 61) was compared to a high-fibre diet (n = 53) over a 24-month period.'? After 12 months' treatment, pain and abdominal distension significantly improved (P < 0.01) in the OB + normal diet group compared with baseline levels. Thus, OB seems to be more effective than a highfibre diet in the treatment of IBS. The effect of OB + normal diet on these parameters was maintained after 24 months of treatment (P < 0.01 versus baseline), whereas the highfibre diet group did not show any significant improvement at this time.
A single-blind, cross-over study in 60 patients with IBS was performed to compare the effectiveness of OB (40 mg/day three times daily), mebeverine (135 mg/day three times daily) and placebo (duration: 4 weeks; washout: 2 weeks) on the severity of abdominal symptoms (pain, flatulence, constipation and/or diarrhoea, and overall efficacy}."! The results for each symptom/patient and overall clinical assessment showed a significant advantage (P < 0.001) in favour of the two drugs versus placebo. There was no significant difference in the overall clinical assessment between OB and mebeverine.
In another single-blind, cross-over study of 40 patients with IBS, treatment with OB (40 mg/day three times daily) significantly (P < 0.05) reduced the number of painful episodes per day compared with pinaverium bromide (50 mg/day three times daily; washout: 2 weeksl.v The intensity of pain, nausea, vomiting and headache were lower with OB, although there was no significant difference between either treatment. The patients' preference was for OB (P < 0.01).
An open-label trial was carried out in Belgium by general practitioners in 1239 patients to evaluate the efficacy of OB (40 mg/day three times daily for 1 or 2 months). The development of symptoms of distension and dyspepsia, abdominal pain, abdominal pain at physical exploration, abnormal defaecations, vegetative syndrome, palpitations and vertigo were assessed (combined score) on a 10-point scale.v A significant difference between baseline and end-of-treatment values was observed for all parameters studied (P < 0.005).
A comparative study with 100 patients with IBS, selected using the Drossman criteria." showed that treatment with OB (40 mg/day three times daily) for 4 weeks resulted in a significant (P < 0.01) improvement in symptomatology compared with baseline values." For a further 8 weeks, 50 patients continued treatment with OB 218 and the other 50 received mebeverine (135 mg/day three times daily). During this period, significantly more (P < 0.01) patients in the OB treatment group discontinued treatment or reduced their consumption of tablets.
ENDOSCOPY STUDIES
The effect of OB (n = 394) compared with placebo or reference drug (n = 484) in reducing intestinal spasm during endoscopy was investigated in four comparative clinical trials.?" -49 A significant reduction in motion activity and improvement in tolerance was observed in the OB-pretreated group compared with placebo. In comparison with the reference drug atropine, OB increased patient tolerability, and ceruletide had a similar effect to OB.
SAFETY
Studies investigating OB have not detected any clinically significant side-effects.F'r'" Those side-effects reported were minor and similar to those found with placebo (e.g. nausea, fatigue, epigastric pain and vertigo). In one study involving 318 patients with IBS, only two patients treated with OB and one with placebo were withdrawn from the study."
CONCLUSIONS
Preclinical and clinical results summarized in this review substantiate the effectiveness of OB in the treatment of altered motility and sensitivity in patients with IBS. The pharmacokinetic profile of OB has shown that it is poorly absorbed and selectively uptaken in the lower gastrointestinal tract. This uptake results in a localized activity and excellent tolerability. The spasmolytic mechanism of action seems to be related to muscarinic receptors, tachykinin NK z receptors and calcium channel blocker properties. Clinical trials have confirmed that, by regulating intestinal motility and sensitivity, DB can greatly reduce symptoms, such as abdominal pain, and improve the quality of life in patients with IBS. 
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